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ill SCUBE1 Solve the
schemia Marker Deficit?*
. Franklin Peacock, MD, FACEP
leveland, Ohio
n this issue of the Journal, Dai et al. (1) report their
ndings regarding plasma SCUBE1. This marker, a protein
ssociated with platelet-endothelial interactions, may be
ndicative of platelet activation occurring during acute
schemic events. The significance of detecting this interac-
ion is its potential as a nonspecific indicator of acute
schemia. Dai et al. (1) report that SCUBE1 is elevated in
oth acute coronary syndromes (ACS) and acute ischemic
troke (AIS), while being undetectable in healthy control
ubjects and chronic coronary artery disease. SCUBE1
oncentrations were also related to stroke severity, and
orrelated with sCD40L, thus providing support that it
eflects platelet activation indicative of acute thrombosis.
See page 2173
This, therefore, begs the question “what is the value in
etecting platelet activation?” The answer lies in our under-
tanding that thrombosis plays a principal role in ACS/AIS
athogenesis. In fact, beyond diagnosis, many of our most
ffective therapies (aspirin, P2Y12 inhibition, 2b3a antago-
ists, and so on) rely on interrupting pathways of platelet
ctivation. Thus, in the proper clinical setting, detecting
hrombosis may help solve one of the challenges in evalu-
ting patients presenting to the hospital with symptoms
onsistent with a thrombotic event: our inability to detect
schemia that prefaces infarction. While current tools detect
yocardial necrosis reasonably well (e.g., troponin), they are
lind for ischemia without necrosis, and no good serum test
or cerebral ischemia exists. SCUBE1 is also promising by
ts signal that it may overcome the weakness of many risk
tratification tools (e.g., C-reactive protein): the inability to
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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nd he also has ownership interest in Vital Sensors.ifferentiate long-term risk that does not need emergency
ntervention, from an acute event requiring immediate
ife-saving therapy.
What is the potential role for SCUBE1? With the
xception of the occasional individual with dynamic elec-
rocardiogram (ECG) changes, our approach for chest pain
s to use highly specific grossly insensitive testing to deter-
ine who has newly dead myocardium. By this strategy,
dentifying who will benefit from an intervention requires
ell death to have already happened. And for AIS, we can
ule in events with imaging, but no rapid blood test
ccurately excludes brain ischemia. The ability to identify a
atient at risk for cell death, before it actually occurs, would
epresent an important advance for patients presenting with
uspected ACS or AIS.
An accurate ischemia marker represents one of the large
nmet needs in contemporary medicine. Beyond selected
CS markers, our existing risk stratification tools are blunt
n the acute care environment. Our strategies are driven
lmost entirely by “ruling in” disease. Nowhere in the early
valuation of ACS or AIS can we definitively exclude
schemia. By focusing on cell death, rather than the process
f cell injury, we lose the ability to prevent necrosis. While
here is great value in treating patients who have suffered
ellular death, it is the vascular equivalent of closing the
arn door after the horse is gone.
If validated, an accurate ischemia marker will change
edicine. This is no exaggeration. Cardiovascular disease
ACS and AIS) is the big one; 79 million U.S. adults (1 of
very 3) suffer from it, and a cardiovascular disease death
ccurs every 2.8 s (2). Who needs an ischemia marker? That
ould be the overcrowded U.S. emergency departments
here patients with suspected ischemia present. It is pre-
icted that in 2008 there will be 11.2 million emergency
epartment visits for chest pain. While the numbers for
troke mimics are less clear, they too are certainly in the
illions. This is a problem. Our diagnostic tools are limited
nd the risks are high. Patients discharged in the throes of
mpending ACS suffer disproportionate morbidity and mor-
ality, and missed myocardial infarction represents the
ighest malpractice award for emergency physicians. On the
erebral side, patients with transient ischemic attack suffer a
.5% and 8.0% risk of stroke in the following 2 and 30 days,
espectively, with their inappropriate discharge representing
n opportunity lost (3).
While some presentations are clearly low risk, some result
n acute mortality, and separating these groups is difficult. In
atients presenting with suspected myocardial ischemia,
2-lead ECG-diagnosed ST-segment elevation myocardial
nfarction identifies the highest-risk cohort, but occurs in only
% of all chest pain patients (4). Unfortunately, for both
CS/AIS the majority of presentations fall into the gray zone
here unclear risk drives a number of testing strategies.
As recently as 10 years ago, emergency physicians madedmission and discharge decisions based solely on clinical
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Editorial Comment June 3, 2008:2181–3rounds. But inaccuracy caused errors, some with adverse
utcomes, and emergency physicians collectively lowered
heir admission threshold. The addition of rapid turnaround
roponin assays helps to identify high-risk patients, but a
ritical sensitivity deficit still exists. Acute coronary syn-
romes cannot be excluded with troponin. In one emer-
ency department study of low-risk emergency department
atients (5), troponin had a specificity and sensitivity of
9.2% and 9.5%, respectively, for predicting acute adverse
vents. While troponin confirms a diagnosis and identifies
nterventional need (e.g., percutaneous coronary interven-
ion), it does not exclude the presence of disease, which is
ritically needed in the emergency department. On the
troke side, with no marker whatsoever, we rely on advanced
maging (e.g., computed tomography/magnetic resonance
maging angiographic and perfusion studies) with both time
nd interpretation challenges that make it difficult to rapidly
xclude cerebral events. A marker that excluded thrombosis
ould allow the physician to focus on other reasons for the
atient’s presentation. While an event marker (e.g., necro-
is) is helpful, in the “clinical value” hierarchy, this is not
ptimal. Better yet would be a marker indicating an adverse
vent is about to occur. Best would be a marker that reliably
xcluded ischemia.
To address the inability to exclude ACS, chest pain
enters (CPCs) have been developed, and the Society of
hest Pain was formed to insure appropriate quality pro-
esses. They allow serial markers and provocative testing to
e performed without in-patient hospitalization. And they
ork. In one before-and-after study of 4,477 patients,
ugelmass et al. (6) reported CPC use decreased mortality
nd increased discharges by a whopping 37% and 36%,
espectively. This process rarely concludes with a discharged
atient suffering a short-term adverse event. But this ad-
antage only occurs at great cost in time and resources.
ingle-visit charges can exceed $4,500, and CPC use has
kyrocketed, with ever lower-risk patients being admitted
or evaluation. Some centers now report 98% of all CPC
valuations are negative (7,8). The math is obvious; we have
vercome the sensitivity deficit of necrosis markers by
roviding extensive work up for nearly all emergency de-
artment patients with chest pain. And recently a similar
rend began occurring with suspected stroke, where patients
re admitted to observation units for more and more
xtensive evaluations. Although time consuming and expen-
ive, these strategies provide the most accurate diagnoses in
medical climate driven to a “miss rate” approaching zero.
Are there any real serum ischemia markers currently
vailable? Both ischemia modified albumin and myeloper-
xidase have Food and Drug Administration approval for
se as risk stratification tools in ACS, but they suffer from
imited clinical use. Although ischemia modified albumin
as a more extensive database, neither marker has been
valuated in an all comer prospective trial where the results
f clinical decision making based on these analytes are
eported. Risk stratification of suspected ACS/AIS can be a sicey game. Any new marker must at least meet the 95%
ensitivity standard obtainable by current clinical practice.
Where does SCUBE1 fit in? The report in this issue of
he Journal is a significant clinical investigation for this
arker. It appears promising. Its biology seems consistent
ith the genesis of ischemia. Its elevation in both AIS and
CS provide consistency of mechanism, a relationship to
everity of illness is suggested, and its lack of elevation in
on-ACS diseased control subjects suggests that it may
ave some degree of sensitivity.
But as to the question of “can we use SCUBE1 today,”
he answer is a short “no,” and much work remains before
e can determine if that deserves to change. A number of
mportant questions must first be answered:
. This was a tube and bottle study; a commonly used
method to improve the pathophysiological understand-
ing of an analyte with potential value. While the results
are promising, this methodology provides minimal un-
derstanding of the clinical consequences if patient care
was based solely on SCUBE1 results.
. Per the protocol, the 40 patients in the ACS group
could be enrolled up to 120 h after onset. Since patients
may present earlier than 120 h, this is a major limitation,
and changes the conclusion to “in patients presenting up
to 5 days after symptom onset, SCUBE1 may identify
ACS.”
. Understanding the early kinetics of SCUBE1 is critical.
In the acute care setting, if SCUBE1 is a late riser, it is
a dead horse. A late-rising marker will not have ade-
quate sensitivity to exclude ischemia at presentation, and
a nonspecific answer 3 days later will have limited
applicability.
. The effects of confounders on SCUBE1 must be much
more detailed. What is the impact of body mass index,
renal dysfunction, and age? Does a hematoma elevate
SCUBE1, what is the effect of trauma, and what
happens with an intramuscular injection? Furthermore,
since we do not know the rate of daily or hourly
SCUBE1 changes in large populations (is it elevated
every time you brush your teeth?), much more under-
standing is needed before clinical use can be considered.
. Pre-test odds of disease drive predictive values. When
highly selected populations are used to evaluate test
performance, as in this study, the results can be remark-
ably different when they are used in an “all-comers”
suspected ischemia population. Many conditions caus-
ing platelet activation are likely to result in elevated
SCUBE1. We need to know how SCUBE1 works in
real life patients before we can use this marker.
e clearly need a sensitive ischemia marker. This study
oes not tell us if SCUBE1 can insure the absence of
schemia anywhere in the patient. Nor can it tell us if
CUBE1 will allow enough early safe discharges of the
uspected ACS/AIS patient in the acute care population to
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June 3, 2008:2181–3 Editorial Commentustify its expense and the probability that some rate of false
ositives will drive increased negative evaluations.
These limitations do not detract from the potential of
CUBE1. We already have a signal that it will not be
levated in every single patient, as the 40 normal subjects
nd 83 nonacute diseased control subjects in this study had
ndetectable levels. Furthermore, the mechanism of
CUBE1 suggests that it may rise even before necrosis. If
his holds true as additional research is performed, it will be
very important marker. Will an early intervention based on
nitial SCUBE1 levels prevent a subsequent troponin rise?
an SCUBE1 be mated with other new emerging technol-
gies? Will a normal SCUBE1 and a normal 80-lead ECG
ove us to immediate discharge? Only more study will tell.
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